Absci Corp

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Absci Corp reports solid Q1 performance, highlights platform efficiency

Absci Corp's Q1 2024 performance reflects a focus on innovation with significant R&D investment and revenue generation, supported by a strong cash position
The company's hybrid business model and progress on internal pipeline programs showcase efficiency and commitment to advancing multiple therapeutic candidates

Absci Corp reports strong Q2 earnings, expands oncology programs

Absci Corp's Q2 2024 earnings call highlighted strong financials, progress in pipeline programs, and strategic collaborations with MSK and other partners.
The company's focus on immunology and oncology, supported by AI capabilities and a healthy cash position, positions Absci for future growth and innovation.
While facing challenges in managing R&D expenses and advancing validation studies, Absci has opportunities to drive innovation and establish a leading position in the market.
Overall, Absci's performance in Q2 2024 reflects a company poised for growth, with a solid foundation to drive research, development, and strategic partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

VANCOUVER, Wash. and NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating virtually in the upcoming B. Riley Securities' Life Sciences Tools Conference - Proteomics Setting the Blueprint for Innovative Drug Creation.

Absci to Participate in the B. Riley Securities' Life Sciences Tools Conference - Proteomics Setting the Blueprint for Innovative Drug Creation

VANCOUVER, Wash. and NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating virtually in the upcoming KeyBanc Capital Markets Life Sciences & MedTech Investor Forum.

Absci to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Generative AI technology, like ChatGPT, is disrupting many industries including biopharma. For example, Absci is using AI to design & validate de novo antibodies.

Absci Takes Its Generative AI Antibody Design Platform To Europe

VANCOUVER, Wash. and NEW YORK, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming 43rd Annual Cowen Health Care Conference. Absci's management is scheduled to participate in a panel discussion and a fireside chat, the details of which are below.

Absci to Participate in the 43rd Annual Cowen Health Care Conference

Absci's generative AI and wet lab capabilities combined with St. John's Cancer Institute's molecular database of cancer patient specimens will accelerate the development of immunotherapies.

St. John's Cancer Institute Partners with Absci to Expedite Development of Cancer Therapies

In silico antibody design expert Dr. Victor Greiff, synthetic biology pioneer Dr. Timothy Lu, and translational medicine veteran Dr. Hubert Truebel will strengthen Absci's scientific leadership in biologic drug creation. In silico antibody design expert Dr. Victor Greiff, synthetic biology pioneer Dr. Timothy Lu, and translational medicine veteran Dr. Hubert Truebel will strengthen Absci's scientific leadership in biologic drug creation.

Absci Deepens Scientific Advisory Board to Accelerate Generative AI Drug Creation

VANCOUVER, Wash. and NEW YORK, Jan. 08, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Absci to Participate in the 41st Annual J.P. Morgan Healthcare Conference

VANCOUVER, Wash. and NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming Berenberg Discover AI Seminar in New York, NY.

Absci to Participate in the Berenberg Discover AI Seminar

VANCOUVER, Wash. and NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York, NY.

Absci to Participate in the Piper Sandler Healthcare Conference

Absci Corporation (ABSI) delivered earnings and revenue surprises of -11.11% and 32.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Absci Corporation (ABSI) Reports Q3 Loss, Tops Revenue Estimates

Milestone achievement and progress continues in previously announced Merck collaboration

Absci Reports Third Quarter 2022 Financial Results

VANCOUVER, Wash. and NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), leaders in the protein drug creation revolution harnessing generative AI and scalable biological data to design better therapeutics, faster, today announced the company will be participating in the upcoming Stifel Healthcare Conference in New York, NY.

Absci to Participate in the Stifel Healthcare Conference

VANCOUVER, Wash. and NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), leaders in the protein drug creation revolution harnessing generative AI and scalable biological data to design better therapeutics, faster, today announced the company will be participating in the upcoming Credit Suisse Annual Healthcare Conference in Rancho Palos Verdes, CA.

Absci to Participate in the 31st Annual Credit Suisse Healthcare Conference

- Dr. Busch transitions from Absci's Board of Directors to Absci's Executive Leadership team -With a proven track record advancing drugs from discovery to market, Dr. Busch brings world-class R&D expertise to Absci's executive leadership team

Absci Appoints Veteran Pharma Executive Andreas Busch, PhD as Chief Innovation Officer

VANCOUVER, Wash. and NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the company will present at the upcoming Inaugural Gilmartin Group Emerging Growth Company Showcase, taking place virtually.

Absci to Participate at the Inaugural Gilmartin Group Emerging Growth Company Showcase

Absci Corporation (ABSI) delivered earnings and revenue surprises of 0% and 38.53%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates

Exceeded annual Active Program guidance with ten programs signed year-to-date

Absci Reports Second Quarter 2022 Financial Results and Business Update

Publicly traded biotech company Absci lays off employees, citing ‘macro-economic conditions'

Axcella Health Inc

DiCE Molecules Holding LLC

Freeline Therapeutics Holdings

 Pliant Therapeutics

Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.

5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

VANCOUVER, Wash. and NEW YORK, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summit Conference in Dana Point, CA.

Absci to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit Conference

VANCOUVER, Wash. and NEW YORK, July 21, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating virtually in the upcoming SVB Securities CybeRx: Big Data, A.I. & Machine Learning in Healthcare Event.

Absci to Participate in the SVB Securities CybeRx: Big Data, A.I. & Machine Learning in Healthcare Event

VANCOUVER, Wash. and NEW YORK, July 14, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced two senior executive hires in newly created roles as it prepares for its next stage of growth.

Absci Prepares for Next Stage of Growth with Executive Human Resources and Marketing Hires

Seven program deal with stealth-mode ADC company to leverage Absci's Bionic Protein™ technology Seven program deal with stealth-mode ADC company to leverage Absci's Bionic Protein™ technology

Absci Enters Multi-Program Collaboration with Emerging Biotech Partner

VANCOUVER, Wash., May 11, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today reported financial and operating results for the quarter ended March 31, 2022.

Absci Reports First Quarter 2022 Financial and Operating Results

Absci, the Vancouver, Wash.-based biotech that provides drug and drug target discovery services to other companies, has opened a lab in New York City. The company announced the opening of the Absci AI Research Lab in Manhattan's Plaza District on Wednesday, saying that the space with panoramic views of Central Park is “designed to energize and inspire innovation.” The AAIR Lab will build on the company's recent breakthroughs in machine learning for in silico antibody lead optimization, as well as its announcement of its collaboration with NVIDIA. It will also advance Absci's therapeutic protein design. “We're eager to tap into the deep… Read More

News for Absci Corp Stock (ABSI)